4553 TOWA PHARMACEUTICAL CO.,LTD. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4553

TSE Prime

TOWA PHARMACEUTICAL CO.,LTD.

3,350

JPY

+95

(+2.92%)

Dec 5, 1:25 pm JST

21.61

USD

Dec 4, 11:27 pm EST

Result

PTS

outside of trading hours

3,350.5

Dec 5, 1:23 pm JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2022	165,615	19,205	22,739	15,914	323.4	60	May 13, 2022	J-GAAP
Mar, 2023	208,859	5,514	5,141	2,201	44.7	60	May 15, 2023	J-GAAP
Mar, 2024	227,934	17,647	24,477	16,173	328.6	60	May 14, 2024	J-GAAP
Mar, 2025	259,594	23,242	26,152	18,986	385.7	70	May 15, 2025	J-GAAP
Mar, 2026 Guidance	280,000	27,000	25,300	17,700	359.6	80	May 15, 2025	J-GAAP
YoY	+7.9%	+16.2%	-3.3%	-6.8%	-6.8%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2021	May 14, 2020	150,000	14,300	14,800	10,400	44	J-GAAP
	Feb 12, 2021	153,000	19,500	17,500	12,600	44	J-GAAP
Results	May 14, 2021	154,900	19,923	18,677	13,958	44	J-GAAP
Mar, 2022	May 14, 2021	Available in future release
	Oct 26, 2021
	Feb 14, 2022
Results	May 13, 2022
Mar, 2023	May 13, 2022
	Nov 14, 2022
	Feb 7, 2023
	Feb 13, 2023
	May 10, 2023
Results	May 15, 2023
Mar, 2024	May 15, 2023
	Feb 13, 2024
Results	May 14, 2024
Mar, 2025	May 14, 2024
	Aug 8, 2024
	Nov 5, 2024
	Feb 13, 2025
	May 7, 2025
Results	May 15, 2025
Mar, 2026	May 15, 2025	280,000	27,000	25,300	17,700	80	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2001	18,406	-8.5	Available in future release
Mar, 2002	19,666	+6.8
Mar, 2003	21,046	+7.0
Mar, 2004	23,124	+9.9
Mar, 2005	24,763	+7.1
Mar, 2006	24,193	-2.3
Mar, 2007	29,235	+20.8
Mar, 2008	31,495	+7.7
Mar, 2009	35,966	+14.2
Mar, 2010	39,043	+8.6
Mar, 2011	46,145	+18.2
Mar, 2012	48,719	+5.6
Mar, 2013	55,241	+13.4
Mar, 2014	61,351	+11.1
Mar, 2015	71,470	+16.5
Mar, 2016	82,115	+14.9
Mar, 2017	84,949	+3.5
Mar, 2018	93,430	+10.0
Mar, 2019	105,104	+12.5
Mar, 2020	110,384	+5.0
Mar, 2021	154,900	+40.3
Mar, 2022	165,615	+6.9
Mar, 2023	208,859	+26.1
Mar, 2024	227,934	+9.1
Mar, 2025	259,594	+13.9
Mar, 2026 Guidance	280,000	+7.9	27,000	+16.2	25,300	-3.3	359.6	-6.8

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Mar, 2024	227,934	17,647	7.74	11.05	4.03	0.57	328.6
Mar, 2025	259,594	23,242	8.95	11.59	4.21	0.58	385.7
Mar, 2026 Guidance	280,000	27,000	9.64	9.84	3.68	0.58	359.6

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	259,594	23,242	26,152	18,986	385.7
Fiscal Year	Mar, 2025	Mar, 2025	Mar, 2025	Mar, 2025	Mar, 2025

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2022	118,359	2,294	532	-491	-10.0	30	May 15, 2023	J-GAAP
Oct - Mar, 2023	120,538	10,644	14,244	9,220	187.3	30	May 14, 2024	J-GAAP
Oct - Mar, 2024	136,190	12,729	15,814	12,431	252.5	40	May 15, 2025	J-GAAP
Oct - Mar, 2025 Guidance	149,524	16,557	13,321	9,486	192.7	40	Nov 10, 2025	J-GAAP
YoY	+9.8%	+30.1%	-15.8%	-23.7%	-23.7%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Mar, 2023	5,514	-27,740	2,544	-30,284	17,481	24,257	6.53	J-GAAP
Mar, 2024	17,647	-32,182	8,212	-40,394	35,407	29,650	6.88	J-GAAP
Mar, 2025	23,242	-7,886	23,401	-31,287	21,567	45,460	9.66	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 2nd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Sep, 2023	107,396	7,003	10,233	6,953	141.3	41.8	Nov 13, 2023	J-GAAP
Apr - Sep, 2024	123,404	10,513	10,338	6,555	133.2	39.5	Nov 12, 2024	J-GAAP
Apr - Sep, 2025	130,476	10,443	11,979	8,214	166.9	47.3	Nov 10, 2025	J-GAAP
YoY	+5.7%	-0.7%	+15.9%	+25.3%	+25.3%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2023	60,929	6,201	6,936	4,565	92.8	10.2	Feb 13, 2024	J-GAAP
Jan - Mar, 2024	59,609	4,443	7,308	4,655	94.6	7.5	May 14, 2024	J-GAAP
Apr - Jun, 2024	62,566	5,672	8,593	5,495	111.6	9.1	Aug 8, 2024	J-GAAP
Jul - Sep, 2024	60,838	4,841	1,745	1,060	21.5	8.0	Nov 12, 2024	J-GAAP
Oct - Dec, 2024	70,333	8,098	11,418	8,069	163.9	11.5	Feb 13, 2025	J-GAAP
Jan - Mar, 2025	65,857	4,631	4,396	4,362	88.6	7.0	May 15, 2025	J-GAAP
Apr - Jun, 2025	65,149	5,206	3,953	2,513	51.1	8.0	Aug 7, 2025	J-GAAP
Jul - Sep, 2025	65,327	5,237	8,026	5,701	115.8	8.0	Nov 10, 2025	J-GAAP
YoY	+7.4%	+8.2%	+359.9%	+437.8%	+437.9%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2020	40,611	+39.8	Available in future release
Jan - Mar, 2021	39,649	+52.6
Apr - Jun, 2021	42,927	+13.3
Jul - Sep, 2021	39,327	+7.0
Oct - Dec, 2021	43,359	+6.8
Jan - Mar, 2022	40,002	+0.9
Apr - Jun, 2022	45,372	+5.7
Jul - Sep, 2022	45,128	+14.8
Oct - Dec, 2022	49,905	+15.1
Jan - Mar, 2023	68,454	+71.1
Apr - Jun, 2023	54,548	+20.2
Jul - Sep, 2023	52,848	+17.1
Oct - Dec, 2023	60,929	+22.1
Jan - Mar, 2024	59,609	-12.9
Apr - Jun, 2024	62,566	+14.7
Jul - Sep, 2024	60,838	+15.1
Oct - Dec, 2024	70,333	+15.4
Jan - Mar, 2025	65,857	+10.5
Apr - Jun, 2025	65,149	+4.1
Jul - Sep, 2025	65,327	+7.4	5,237	+8.2	8,026	+359.9	115.8	+438.6

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	70,333	8,098	11,418	8,069	163.9
Fiscal Year	Dec, 2024	Dec, 2024	Dec, 2024	Dec, 2024	Dec, 2024

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Mar, 2023	2,781.17	36.9	371,347	136,894	121,232	1.18	May 15, 2023	J-GAAP
Mar, 2024	3,167.27	36.2	430,653	155,893	134,452	1.30	May 14, 2024	J-GAAP
Mar, 2025	3,486.40	36.5	470,823	171,625	150,502	1.35	May 15, 2025	J-GAAP
Apr - Sep, 2025	ー	37.4	480,530	179,863	156,747	1.31	Nov 10, 2025	J-GAAP

TOWA PHARMACEUTICAL CO.,LTD.(4553) Financial Results